



Translation

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation
September 1, 2026

**Notice Regarding the Conclusion of a Basic Agreement Pertaining to the
Commercialization of Next-Generation Veterinary Healthcare Platform
Between 12 Pharmacy Inc., animo Co., Ltd., and Alfresa Corporation**
Improvement of operational efficiency of veterinary clinics and convenience for pet owners
and creation of new veterinary healthcare field services

Subsidiary Alfresa Corporation (head office: Chiyoda-ku, Tokyo; representative director & president: Yusuke Fukujin; hereinafter “Alfresa”) has concluded a basic agreement with 12 Pharmacy Inc. (head office: Setagaya-ku, Tokyo; representative director: Genki Ishihara; hereinafter “12 Pharmacy”) and animo Co., Ltd. (head office: Hokuto City, Yamanashi Prefecture; representative director & president: Atsushi Kurita; hereinafter “animo”) regarding the commercialization of a next-generation veterinary healthcare platform. The details of this agreement are as follows.

1. Background and Purpose of the Agreement

With more families welcoming pets into their homes and the increasing average lifespans of pets, awareness regarding the health of pets has been on the rise. This trend is creating needs related to ongoing veterinary healthcare management and services. At the same time, veterinary clinics are increasingly being expected to provide a diverse range of peripheral services related to examinations, such as drug formulation, pharmaceutical ordering and inventory management, and explanations concerning pharmaceutical administration to pet owners. These services must be provided in addition to examinations. Meanwhile, there are growing calls among pet owners for highly convenient services that reduce waiting times at veterinary clinics while also shortening travel distances to said clinics and allowing for ongoing monitoring of the health status of their pets.

The Alfresa Group is in the process of expanding and transforming its business portfolio based on its Medium- to Long-Term Vision,^{*1} which describes the growth strategies it will be implementing leading up to fiscal 2032. As one facet of these strategies, we are exploring the possibility of developing new businesses related to

the digital transformation for veterinary clinic operations, support solutions for veterinarians and pet owners, and the veterinary healthcare supply chain.

According to the basic agreement, the three companies will seek to develop a new information linkage platform for connecting veterinary clinics and pet owners. In this undertaking, all parties will examine the feasibility of augmenting not only the functions of the online prescription system^{*2} and formulation and delivery services of veterinary pharmacy operator 12 Pharmacy but also the platforms for pet owners and veterinarians as well as the health information data platforms of veterinary healthcare support company animo. The possibility of interconnecting these systems and platforms will also be examined. The aforementioned initiatives will be advanced in pursuit of improved efficiency in examination-related peripheral services at veterinary clinics and of increased convenience for pet owners. Collaboration will also be practiced with the goal of commercializing a next-generation veterinary healthcare platform that could potentially involve the creation of new services.

In this project, 12 Pharmacy will contribute the insight related to formulation and delivery operations it has gained through the provision of specialized veterinary dispensing pharmacy services and online prescription systems. Meanwhile, animo will provide its expertise in infrastructure development, the analysis of real-world veterinary data^{*3}, and the planning and production of related services. Alfresa will utilize its track record regarding the development of services for improving operational efficiency at healthcare institutions, support for the introduction of such services, and pharmaceutical distribution in order to promote business planning and service development by the three companies.

*1 Reference: Notice regarding the Formulation of the Alfresa Group's Medium- to Long-Term Vision (published on May 15, 2023, on the Alfresa Holdings Corporation corporate website) https://www.alfresa.com/eng/ir/pdf/mediumtolong_termvision.pdf

*2 The online prescription system allows for prescription information to be shared by veterinary clinics with dispensing pharmacies via the internet and differs from the electronic prescription system operated by the national government.

*3 Real-world veterinary data refers to data collected from everyday veterinary health examinations and pet living conditions.

2. Outline of the Basic Agreement

Under the basic agreement, 12 Pharmacy, animo, and Alfresa will engage in collaboration with the following aims.

- (1) Development of systems related to formulation services that provide online prescription and other features for veterinary clinics and pet owners
- (2) Establishment of information linkage platforms utilizing said systems
- (3) Planning of businesses and development of services for the veterinary healthcare field

Collaboration Framework

Three-Partner Initiatives for Commercialization of Next-Generation Veterinary Healthcare Platform



3. Overview of Agreement Partners

(1) 12 Pharmacy (As of July 31, 2026)

i.	Corporate name	12 Pharmacy Inc.	
ii.	Head office	6-33-36, Minami-karasuyama, Setagaya-ku, Tokyo	
iii.	Name and title of representative	Genki Ishihara, Representative Director	
iv.	Description of business	Operation of veterinary dispensing pharmacies, retailing and wholesaling of pharmaceutical and medical products, and planning, development, sales, and maintenance of computer systems	
v.	Paid-in capital	¥92 million	
vi.	Date of founding	May 2, 2023	
vii.	Relationship between Alfresa Holdings Corporation, Alfresa Corporation, and 12 Pharmacy Inc.	Capital relationship	None
		Human relationship	None
		Transactional relationship	None
		Related parties	None

(2) animo (As of July 31, 2026)

i.	Corporate name	animo Co., Ltd.* ⁴	
ii.	Head office	3332-1239, Aza Shinohara, Kamisasao, Kobuchisawa-cho, Hokuto City, Yamanashi Prefecture	
iii.	Name and title of representative	Atsushi Kurita, Representative Director & President	
iv.	Description of business	Provision of business support for the veterinary healthcare field and supply of the animo platform for connecting pet owners and veterinarians	
v.	Paid-in capital	¥15 million	
vi.	Date of founding	September 26, 2023	
vii.	Relationship between Alfresa Holdings Corporation, Alfresa Corporation, and animo Co., Ltd.	Capital relationship	None
		Human relationship	None
		Transactional relationship	None
		Related parties	None

*4 animo is a subsidiary of CMIC HOLDINGS Co., Ltd.

4. Schedule Regarding Agreement

Conclusion of basic agreement: August 25, 2026

5. Outlook

While the impact of this agreement on business performance for the fiscal year ending March 31, 2027 is expected to be minimal at the current time, we believe it will contribute to the enhancement of the Group's corporate value over the medium to long term.

We will promptly announce any matters that need to be disclosed regarding this agreement going forward.

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to realizing its mission, “we create and deliver a fresh life for all,” through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, regenerative medicine-related business, and CRO business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥3.1 trillion for the fiscal year ended March 31, 2026. For more information, please see: <https://www.alfresa.com/eng/>